Click Here to learn about our most recent COVID-19 updates including vaccine information, visitor restrictions, testing, and more.

What can we help you find?

Sorry, we couldn't find any content for "{{results_term}}." Try searching again.

COVID-19 Resources

Clinical Trials for COVID-19

As Cincinnati’s academic health system, it is our privilege and our responsibility to be a source of hope for those who need it most. One way we offer hope is through our tireless commitment to research.


Updated: June 14, 2021

As the leaders in research, teaching and clinical care in Greater Cincinnati, the University of Cincinnati, UC Health, Cincinnati Children’s Hospital Medical Center and Cincinnati Department of Veterans Affairs Medical Center are working together in scientific discovery to help treat, prevent and cure COVID-19.

Right now, our researchers are:

  • Learning more about the virus, including transmission, and how it affects people with specific conditions.
  • Studying possible treatment options.
  • Studying why some people get sicker than others.
  • Identifying how many people are infected.
  • Determining how our immune systems will protect us from future infections.

 

ACTIV 2

IRB #2020-0731
The purpose of this voluntary study is to evaluate the ability of various drugs to improve health outcomes for people with COVID-19. Investigators will also study whether these treatment drugs are safe and effective in stopping the disease process and preventing hospitalization.

Study contacts

 

ACTIV 3

IRB #2020-0801

The purpose of this study is to test the safety and efficacy of two types of experimental drugs called neutralizing monoclonal antibodies (nMAbs), either VIR-7831 or BRII-196 + BRII-198, in patients admitted to the hospital with COVID-19. This general type of medicine has been approved to treat many other diseases, but is early in development for treating COVID-19. We are trying to find out if giving this kind of experimental drug can help people in the hospital with COVID-19 get better and go home faster.

Study contacts

ACTIV 4

IRB: 2020-0860
The purpose of this study is to determine if a higher dose blood thinner is better than a lower dose blood thinner in patients hospitalized with COVID-19 disease. The blood thinners used in this study are heparin-related medicines. They are already approved by the FDA for preventing blood clots in different situations. We do not currently know the best dose of these drugs in people hospitalized with COVID-19.

Study contacts

 

CCR Study

IRB# 2020-0329
The CCR trial is a COVID-19 observational study with sample and data collection to provide a mechanism to collect medical record data and specimens (peripheral blood, sputum, nasal swab, oropharyngeal swab, stool, mini bronchoalveolar lavage (BAL), remnant BAL and tissue specimens including post-mortem biopsies) that will provide insights into the pathophysiology of a novel infectious agent, and aid in the development of new diagnostic tools and treatment strategies for patients with COVID-19.

Study contacts

 

MAVRI 2 (KPL-301-C203)

IRB # 2020-0574

This study is a phase 2/3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mavrilimumab (KPL-301) treatment in adult subjects hospitalized with severe COVID-19 pneumonia and hyper-inflammation. Mavrilimumab is a human monoclonal antibody that inhibits GM-CSF receptor. The goal is to minimize cytokine storm and limit lung damage.

Study contacts

Rapid Biomarker

IRB #: 2020-0532
The purpose of this research study is to see if exhaled breath can be used to determine whether someone is COVID-19 positive. Healthy participants will be in the research study for about 30 days. Hospitalized patients will be in the study for 30 days after discharge from the hospital.

The exhaled breath process will take under 10 minutes. Participants will receive a follow-up phone call 30 days after exhaled breath procedure or discharge from the hospital.

This study is sponsored by the United States Air Force.

Study contacts

 

TL-895-202

IRB #: 2020-0566
This study is for those admitted to the hospital with COVID-19 infection who also have cancer. The purpose of this study is to determine if an investigational drug called TL-895 is well-tolerated and an effective treatment to prevent the need for ventilators in cancer patients with COVID-19 infection.

TL-895 has not been approved for the treatment of COVID-19 infection.

This study drug is believed to help decrease lung inflammation by shutting down signals involved with the release of inflammation factors, while not affecting certain cells involved with your body’s natural defense against the virus. There is reason to believe that TL-895 may be able to improve functions of the natural defense cells against the virus and reduce the need to use ventilators.

Study contacts

 

COVID-19 Vaccine Studies

The goal of UC Health and the University of Cincinnati is to host multiple clinical trials designed to evaluate the safety and effectiveness of COVID-19 vaccines.

If you are interested in being contacted in the future about a COVID-19 vaccine trial, please complete this brief survey. Study teams will be reaching out to eligible participants with more information during the enrollment process.

By encouraging participation in our clinical trials, we can help find treatments, cures, and prevention opportunities that could possibly save lives. If you or someone you know has COVID-19 or has recovered from COVID-19 and would be interested in learning more about available trials, please contact UCCovidResearch@uchealth.com or call 513-245-3417.

Our researchers, like our clinicians and staff, have been the embodiment of “In science lives hope” during this pandemic.  We are all working hard to offer hope to our patients, their families, and our communities during this unprecedented time.